Human PD-L1 Protein Recombinant

• Description:

  Human PD-L1 Protein Recombinant_x000D_ Catalog number: B2018489_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 µg_x000D_ Molecular Weight or Concentration: N/A_x000D_ Supplied as: Powder_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -20°C_x000D_ Keywords: PD-L1_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Cotton AD, Nguyen DP, Gramespacher JA, Seiple IB, Wells JA. Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1 J Am Chem Soc. 2021 Jan 20;143(2):593-598._x000D_ 2: Banik SM, Pedram K, Wisnovsky S, Ahn G, Riley NM, Bertozzi CR. Lysosome-targeting chimaeras for degradation of extracellular proteins Nature. 2020 Aug;584(7820):291-297._x000D_ 3: Zhu D, Xu R, Huang X, Tang Z, Tian Y, Zhang J, Zheng X. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1 Cell Death Differ. 2021 Jun;28(6):1773-1789._x000D_ 4: Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H; ORIENT-16 Investigators. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial JAMA. 2023 Dec 5;330(21):2064-2074._x000D_ 5: Lin J, Guo D, Liu H, Zhou W, Wang C, Müller I, Kossenkov AV, Drapkin R, Bitler BG, Helin K, Zhang R. The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity Cancer Immunol Res. 2021 Dec;9(12):1413-1424._x000D_ 6: Cui X, Jia H, Xin H, Zhang L, Chen S, Xia S, Li X, Xu W, Chen X, Feng Y, Wei X, Yu H, Wang Y, Zhan Y, Zhu X, Zhang X. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities Front Immunol. 2021 Dec 2;12:778978._x000D_ 7: Du L, Lee JH, Jiang H, Wang C, Wang S, Zheng Z, Shao F, Xu D, Xia Y, Li J, Zheng Y, Qian X, Li X, Kim HR, Xing D, Liu P, Lu Z, Lyu J. β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion J Exp Med. 2020 Nov 2;217(11):e20191115._x000D_ 8: Sun L, Wang Y, Wang X, Navarro-Corcuera A, Ilyas S, Jalan-Sakrikar N, Gan C, Tu X, Shi Y, Tu K, Liu Q, Lou Z, Dong H, Sharpe AH, Shah VH, Kang N. PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-β receptor I versus II Cell Rep. 2022 Feb 8;38(6):110349._x000D_ 9: Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy J Hematol Oncol. 2019 May 31;12(1):54._x000D_ 10: Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, Huang XF, Chen SY. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses Nat Commun. 2020 Mar 13;11(1):1395. _x000D_ _x000D_ Products Related to Human PD-L1 Protein Recombinant can be found at Proteins

• Short Description:

  Catalog Number: B2018489 (50 µg)_x000D_ Human PD-L1 protein recombinant is a form of the programmed death-ligand 1 (PD-L1) protein produced using recombinant DNA technology. It is utilized in research to study the interaction between PD-L1 and its receptor PD-1, crucial in immune response regulation. Recombinant proteins are generated in labs by inserting the protein-encoding gene into host organisms like bacteria or yeast for research purposes. This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request._x000D_ _x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3